Pressemeddelelse

Modus Therapeutics: New Article on Sevuparin Published in HemaSphere

Stockholm, Sweden, 5 December 2024: Modus Therapeutics announces that a scientific article about the company’s drug candidate, sevuparin, has been published in the respected medical journal HemaSphere. The article, titled "Sevuparin strongly reduces hepcidin expression in cells, mice, and healthy human volunteers," presents findings showing that sevuparin significantly reduces hepcidin levels – a key hormone regulating the body’s iron metabolism.

The study includes data from laboratory research, animal models, and clinical trials involving healthy volunteers. The results demonstrate that sevuparin can reduce elevated hepcidin levels, which are associated with conditions such as anemia in chronic kidney disease and other inflammatory diseases. These findings provide a strong basis for continued development of sevuparin towards the goal to address significant unmet medical needs in this area.

Key findings from the study:

A significant reduction in hepcidin levels, by up to 72%, in healthy volunteers at the highest dose.
Strong inhibitory effects on hepcidin levels observed in preclinical models, contributing a scientific and mechanistic foundation for further development.
The study also confirmed favorable safety profile of sevuparin.

"The publication of these results in HemaSphere is an expression of the successful collaboration and hard work of our teams at the University of Brescia including the first author Michela Asperti and Modus Therapeutics. It highlights the growing scientific evidence supporting the potential of sevuparin in reducing hepcidin levels both in vitro and in vivo. Hepcidin is a key driver of anemia in chronic inflammatory conditions and our findings pave the way for new treatment strategies," says Professor Maura Poli, senior author of the study and research team leader at the University of Brescia.

“These results constitute an integral part of the foundation for our ongoing clinical program in chronic kidney disease with anemia. We are very pleased that our findings can now be shared in a leading medical journal,” says John Öhd, CEO of Modus Therapeutics.

The article is available online at https://onlinelibrary.wiley.com/doi/10.1002/hem3.70035.

Modus Therapeutics continues to focus on advancing the development of sevuparin for the treatment of diseases with high unmet medical needs, including anemia in chronic inflammatory conditions.

About Modus Therapeutics and sevuparin
Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.